Organon & Co.
Rating
Updated: Aug 10, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, en...
Latest News
1 day ago · zacks.com
Is Trending Stock Organon & Co. (OGN) a Buy Now?Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
8 days ago · businesswire.com
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine DeviceJERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
12 days ago · accessnewswire.com
Orogen Royalties Acquires the Serpent Gold Project in NevadaVANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in Nevada, USA. Project Highlights Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration Highly anomalous gold in rocks (up to 0.95 grams per tonne ("g/t") gold) associated with the shallow expression of an epithermal deposit Underexplored with no evidence of historical drilling Generated in partnership with Altius Minerals Corporation The Serpent project is available for option or sale.
14 days ago · zacks.com
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should KnowZacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
20 days ago · accessnewswire.com
Orogen Royalties Acquires Two Gold Projects in Southwest UtahVANCOUVER, BC / ACCESS Newswire / September 2, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA. Project Highlights Two low-sulphidation epithermal targets located in caldera complexes of southwest Utah Toro de Oro is centered on an extensive footprint of steam cap alteration and chalcedonic vein sets indicating the high-level expression of an epithermal system, geologically similar to AngloGold Ashanti's Arthur Project El Gigante contains two separate quartz veins up to and exceeding three metres wide and over 350 metres long with strong similarities to the surface expression of First Majestic's Ermitaño vein.
1 month ago · accessnewswire.com
Orogen Royalties Acquires a Royalty on the Haldane Silver ProjectVANCOUVER, BC / ACCESS Newswire / August 20, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce it has acquired a 2% Net Smelter Return ("NSR") royalty (the "Royalty") on the Haldane silver project in Yukon Territory, Canada. Haldane Royalty Highlights 1,2,3,4 Haldane is a high-grade silver project owned by Silver North Resources Ltd.
1 month ago · accessnewswire.com
Orogen Royalties and Aurum Discovery form Generative Alliance in NorwayVANCOUVER, BC / ACCESS Newswire / August 17, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the formation of a generative exploration alliance (the "Alliance") with a subsidiary of Aurum Discovery ("Aurum"), a private prospect generator based in Ireland. The Alliance will focus on generating gold and silver targets in prospective mineral belts within Norway.
1 month ago · businesswire.com
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial AvailabilityJERSEY CITY, N.J.--(BUSINESS WIRE)--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon's hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.
2 months ago · zacks.com
Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key MetricsAlthough the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2 months ago · zacks.com
Organon (OGN) Lags Q2 Earnings EstimatesOrganon (OGN) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1 per share a year ago.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OGN